MWMengchuan Wang

Mengchuan Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mengchuan Wang has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Aiguo Wu

    Department of General Surgery, Zhujiang Hospital of Southern Medical University, Guangzhou, China

    3 shared publications
  • Kankan Zhao

    Department of Thyroid and Breast Surgery, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan City, P.R. China

    2 shared publications
  • Chaojie Zhang

    State Key Laboratory of Water Pollution Control and Green Resource Recycling, College of Environmental Science and Engineering, Tongji University, Shanghai 200092, PR China; Shanghai Institute of Pollution Control and Ecological Security, Shanghai 200092, PR China; Key Laboratory of Urban Water Supply, Water Saving and Water Environment Governance in the Yangtze River Delta of Ministry of Water Resources, Shanghai 200092, PR China

    1 shared publication
  • Fang Meng

    Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College; Suzhou Institute of Systems Medicine, Suzhou, China

    1 shared publication
  • G. Shao

    Center of Special Medical Care, Zhujiang Hospital, Southern Medical University/The Second School of Clinical Medicine, Guangzhou, Guangdong, People's Republic of China

    1 shared publication
  • Haipeng Tang

    Department of General Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, PR China

    1 shared publication

Latest Publications

  • Open Access

    Viral peptides remodel the tumor immune microenvironment of cold tumors with RNA-seq insights

    by Zhengqi Peng, Qian Chen, Pengkhun Nov, Mohsin Farid Sulehri, Yujing Liu, Hexi Zhu, Wulikaixi Yagufu, Yiteng Chen, Haipeng Tang, Linlang Guo, et al.

  • Open Access

    ATP6AP2 is Overexpressed in Breast Cancer and Promotes Breast Cancer Progression

    by Kankan Zhao, Mengchuan Wang, Aiguo Wu

    Background: Adenosine triphosphatase H+ transporting accessory protein 2 (ATP6AP2), also known as (pro)renin receptor, is implicated in tumorigenesis and the progression of several types of cancer. This study investigated the role of ATP6AP2 in breast cancer. Methods: UALCAN and ONCOMINE datasets were utilized to compare transcript levels of ATP6AP2 in breast cancer and normal tissues. GOBO datasets were applied to examine ATP6AP2 expression in different breast cancer cell lines. We used the cBioPortal website to explore the gene alterations and copy number alterations of ATP6AP2 in breast cancer. Cell Counting Kit-8 and transwell assays were conducted to evaluate ATP6AP2 function in MCF-7 breast cancer cells. Finally, we used the cBioPortal website to establish the interaction network of ATP6AP2 in breast cancer and performed functional enrichment analysis based on Gene Ontology terms and Kyoto Encyclopedia of Genes and Genomes pathways. Results: ATP6AP2 was overexpressed in breast cancer tissues and breast cancer cell lines in the UALCAN, ONCOMINE, and GOBO datasets. The major type of ATP6AP2 alteration was mRNA upregulation. Moreover, ATP6AP2 was most highly expressed in luminal type breast cancer. Finally, ATP6AP2 knockdown reduced MCF-7 cell proliferation, invasion and migration. Functional enrichment analysis suggested that ATP6AP2 regulates several cancer-related pathways, especially the Wnt/β-catenin signaling pathway. Conclusion: Applying multi-dimensional analytical methods, we demonstrate that ATP6AP2 is upregulated in breast cancer and may promote its development and progression.


  • Open Access

    Elevated estrogen receptor β expression in triple negative breast cancer cells is associated with sensitivity to doxorubicin by inhibiting the PI3K/AKT/mTOR signaling pathway

    by Shanshan Lei, Peizhi Fan, Mengchuan Wang, Chaojie Zhang, Yu Jiang, Shulin Huang, Meng Fang, Zili He, Aiguo Wu

    Based on its pathological characteristics, breast cancer is a highly heterogeneous disease. Triple negative breast cancer (TNBC) is an aggressive subtype, and due to a lack of effective therapeutic targets, patients with TNBC do not significantly benefit from endocrine or anti‑HER2 therapy. Conventional chemotherapy has been regarded as the only systemic therapy option for TNBC, but its therapeutic efficacy remains limited. Estrogen receptor β (ERβ) has been identified as a tumor suppressor in TNBC. Therefore, the aim of the present study was to identify the role of ERβ in regulating the response to chemotherapy, and to investigate its underlying mechanism in TNBC. MDA‑MB‑231 and BT549 cells were treated with doxorubicin (DOX), liquiritigenin [Liq, (Chengdu Biopurify Phytochemicals, Ltd.); a specific ERβ agonist], or a combination of DOX and Liq in vitro. The effects of various treatments on cell viability and proliferation were measured using the Cell Counting Kit‑8 and colony‑formation assays, respectively. MDA‑MB‑231 and ERβ knockdown (ERβ‑KD) MDA‑MB‑231 cells were selected for the establishment of ERα‑/ERβ+ and ERα‑/ERβ‑ cell models, respectively. The two cell models were treated with DOX, Liq or a combination of DOX and Liq. The effects of the treatment on the PI3K/AKT/mTOR signaling pathway were evaluated by assessing the protein expression levels of AKT and mTOR using western blot analysis. Low Liq concentrations increased the sensitivity of MDA‑MB‑231 and BT549 cells to DOX. Moreover, the synergistic effect of Liq and DOX treatment was associated with the inhibition of the PI3K/AKT/mTOR signaling pathway in MDA‑MB‑231 cells, and the effect was ERβ‑dependent. The results suggested that elevated ERβ expression was associated with sensitivity to doxorubicin by inhibiting the PI3K/AKT/mTOR signaling pathway; therefore, the combined use of conventional chemotherapeutic drugs with ERβ agonists may serve as an effective therapy for TNBC.


  • Effect of exosome biomarkers for diagnosis and prognosis of breast cancer patients

    by M. Wang, S. Ji, G. Shao, J. Zhang, K. Zhao, Z. Wang, A. Wu

    Exosomes are gradually detected as an indicator for diagnosis and prognosis of breast cancer in clinic and a systematic review was conducted.